March 10, 2025

Baricitinib Effective for Teen Alopecia

Eli Lilly's JAK inhibitor demonstrated 80% scalp hair regrowth in 42.4% of adolescents with severe alopecia areata after just 36 weeks of treatment, outperforming placebo in the Phase 3 BRAVE-AA-PEDS trial.

Conexiant

March 06, 2025

Study Links Pain Relievers to Quicker Concussion Recovery

Researchers will present findings at the American Academy of Neurology’s 77th Annual Meeting on how OTC pain relievers may be linked to faster concussion recovery.

Conexiant

March 05, 2025

AAN: Ideal Dosing of Folic Acid During Pregnancy

Folic acid taken during the first trimester led to improved verbal skills and behavior in children at age 6, with no evidence of negative effects, according to new research to be presented at the American Academy of Neurology's 77th Annual Meeting.

Conexiant

March 03, 2025

Omalizumab Bests Oral Immunotherapy for Food Allergies

"These differences were largely driven by the high rate of adverse events leading to study discontinuation in the OIT-treated participants, despite receiving omalizumab treatment at the initiation of therapy."

Conexiant

October 03, 2023

Ford Dental Institute Announces New 2024 Conference and Speaker Lineup

Ford Dental Institute Announces Conference

AEGIS Dental Network

February 06, 2025

Pediatric Stroke Survivors Show Higher Mental Health Risks

New research reveals children who survive strokes face increased rates of anxiety, depression, and physical symptoms, with age 9 identified as a critical period for mental health challenges, according to findings presented at the 2025 International Stroke Conference.

Conexiant

April 29, 2024

Identifying Common Triggers of Photocontact Dermatitis

Discover how exposure to certain fruits, vegetables, drugs, and plants can trigger symptoms of photocontact dermatitis and the importance of seeking shade and wearing protective clothing in the sun.

Conexiant

June 24, 2024

Survodutide Shows Significant HbA1c Reduction

New clinical trials presented at the American Diabetes Association's Scientific Sessions show that survodutide has promising results for reducing HbA1c levels and improving insulin sensitivity, with additional favorable changes in glucose-related biomarkers.

Conexiant

December 11, 2024

Triple-Drug Combos Show High Response Rates

Cutting-edge triple-drug therapies for leukemia discussed at the American Society of Hematology meeting show promising results in achieving remission and managing residual disease.

Reuters